<DOC>
	<DOC>NCT01421563</DOC>
	<brief_summary>The purpose of this study is compare the safety and pharmacokinetic characteristics of DP-R202 (Sarpogrelate HCl 300mg, qd) with those of Anplag (Sarpogrelate HCl 100mg, tid) after oral administration in healthy male volunteers.</brief_summary>
	<brief_title>Safety and Pharmacokinetic Characteristics of DP-R202 in Healthy Male Volunteers</brief_title>
	<detailed_description>The number of patient is thirthy-six.Patients were randomly assigned either anplag tablet(Sarpogrelate HCL 100mg, tid)first, DP-R202(Sarpogrelate HCL 300mg, qd) Second or DP-R202(Sarpogrelate HCL 300mg, qd) first, anplag tablet(Sarpogrelate HCL 100mg, tid) second.</detailed_description>
	<mesh_term>Sarpogrelate</mesh_term>
	<criteria>20 to 55 years of healthy volunteers Hypersensitivity Reaction about Sarpogrelate HCL or other antiplatelets</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>August 2011</verification_date>
</DOC>